Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism

Jean-Michel Azorin1, Charles L Bowden2, Ricardo P Garay3, Giulio Perugi4, Eduard Vieta5, Allan H Young61Department of Psychiatry, CHU Sainte Marguerite, Marseilles, France; 2Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA; 3CNRS-UMR 8162, Universit&e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jean-Michel Azorin, Charles L Bowden, Ricardo P Garay, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/538d44037c4344408bded6a930aa618e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:538d44037c4344408bded6a930aa618e
record_format	dspace
spelling	oai:doaj.org-article:538d44037c4344408bded6a930aa618e2021-12-02T09:06:44ZPossible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism1176-63281178-2021https://doaj.org/article/538d44037c4344408bded6a930aa618e2010-03-01T00:00:00Zhttp://www.dovepress.com/possible-new-ways-in-the-pharmacological-treatment-of-bipolar-disorder-a4032https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Jean-Michel Azorin1, Charles L Bowden2, Ricardo P Garay3, Giulio Perugi4, Eduard Vieta5, Allan H Young61Department of Psychiatry, CHU Sainte Marguerite, Marseilles, France; 2Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA; 3CNRS-UMR 8162, Universit&eacute; Paris-Sud, and H&ocirc;pital Marie Lannelongue, Le Plessis-Robinson, France; 4Vincent P Dole Dual Diagnosis Team, Santa Chiara and University Hospital, Department of Psychiatry, University of Pisa, Italy; 5Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBER -SAM, Barcelona, Spain; 6Institute of Mental Health, University of British Columbia, Vancouver, CanadaAbstract: About half of all bipolar patients have an alcohol abuse problem at some point of their lifetime. However, only one randomized, controlled trial of pharmacotherapy (valproate) in this patient population was published as of 2006. Therefore, we reviewed clinical trials in this indication of the last four years (using mood stabilizers, atypical antipsychotics, and other drugs). Priority was given to randomized trials, comparing drugs with placebo or active comparator. Published studies were found through systematic database search (PubMed, Scirus, EMBASE, Cochrane Library, Science Direct). In these last four years, the only randomized, clinically relevant study in bipolar patients with comorbid alcoholism is that of Brown and colleagues (2008) showing that quetiapine therapy decreased depressive symptoms in the early weeks of use, without modifying alcohol use. Several other open-label trials have been generally positive and support the efficacy and tolerability of agents from different classes in this patient population. Valproate efficacy to reduce excessive alcohol consumption in bipolar patients was confirmed and new controlled studies revealed its therapeutic benefit to prevent relapse in newly abstinent alcoholics and to improve alcohol hallucinosis. Topiramate deserves to be investigated in bipolar patients with comorbid alcoholism since this compound effectively improves physical health and quality of life of alcohol-dependent individuals. In conclusion, randomized, controlled research is still needed to provide guidelines for possible use of valproate and other agents in patients with a dual diagnosis of bipolar disorder and substance abuse or dependence.Keywords: bipolar disease, alcohol, alcoholism, comorbidity, valproate Jean-Michel AzorinCharles L BowdenRicardo P Garayet alDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 37-46 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Jean-Michel Azorin Charles L Bowden Ricardo P Garay et al Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism
description	Jean-Michel Azorin1, Charles L Bowden2, Ricardo P Garay3, Giulio Perugi4, Eduard Vieta5, Allan H Young61Department of Psychiatry, CHU Sainte Marguerite, Marseilles, France; 2Department of Psychiatry, University of Texas Health Science Center, San Antonio, TX, USA; 3CNRS-UMR 8162, Universit&eacute; Paris-Sud, and H&ocirc;pital Marie Lannelongue, Le Plessis-Robinson, France; 4Vincent P Dole Dual Diagnosis Team, Santa Chiara and University Hospital, Department of Psychiatry, University of Pisa, Italy; 5Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBER -SAM, Barcelona, Spain; 6Institute of Mental Health, University of British Columbia, Vancouver, CanadaAbstract: About half of all bipolar patients have an alcohol abuse problem at some point of their lifetime. However, only one randomized, controlled trial of pharmacotherapy (valproate) in this patient population was published as of 2006. Therefore, we reviewed clinical trials in this indication of the last four years (using mood stabilizers, atypical antipsychotics, and other drugs). Priority was given to randomized trials, comparing drugs with placebo or active comparator. Published studies were found through systematic database search (PubMed, Scirus, EMBASE, Cochrane Library, Science Direct). In these last four years, the only randomized, clinically relevant study in bipolar patients with comorbid alcoholism is that of Brown and colleagues (2008) showing that quetiapine therapy decreased depressive symptoms in the early weeks of use, without modifying alcohol use. Several other open-label trials have been generally positive and support the efficacy and tolerability of agents from different classes in this patient population. Valproate efficacy to reduce excessive alcohol consumption in bipolar patients was confirmed and new controlled studies revealed its therapeutic benefit to prevent relapse in newly abstinent alcoholics and to improve alcohol hallucinosis. Topiramate deserves to be investigated in bipolar patients with comorbid alcoholism since this compound effectively improves physical health and quality of life of alcohol-dependent individuals. In conclusion, randomized, controlled research is still needed to provide guidelines for possible use of valproate and other agents in patients with a dual diagnosis of bipolar disorder and substance abuse or dependence.Keywords: bipolar disease, alcohol, alcoholism, comorbidity, valproate
format	article
author	Jean-Michel Azorin Charles L Bowden Ricardo P Garay et al
author_facet	Jean-Michel Azorin Charles L Bowden Ricardo P Garay et al
author_sort	Jean-Michel Azorin
title	Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism
title_short	Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism
title_full	Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism
title_fullStr	Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism
title_full_unstemmed	Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism
title_sort	possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/538d44037c4344408bded6a930aa618e
work_keys_str_mv	AT jeanmichelazorin possiblenewwaysinthepharmacologicaltreatmentofbipolardisorderandcomorbidalcoholism AT charleslbowden possiblenewwaysinthepharmacologicaltreatmentofbipolardisorderandcomorbidalcoholism AT ricardopgaray possiblenewwaysinthepharmacologicaltreatmentofbipolardisorderandcomorbidalcoholism AT etal possiblenewwaysinthepharmacologicaltreatmentofbipolardisorderandcomorbidalcoholism
_version_	1718398243001335808

Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism

Ejemplares similares